U.S. Life Sciences Stock News

NYSE:RPC
NYSE:RPCCapital Markets

Ridgepost Capital (RPC) Valuation Check After Rebrand And High P/E Versus Peers

Why Ridgepost Capital Is On Investors’ Radar Ridgepost Capital (RPC) recently rebranded from P10, Inc. This shift is putting fresh attention on how this multi asset class private market solutions provider is positioned across private equity, venture capital, impact investing, and private credit. See our latest analysis for Ridgepost Capital. At a latest share price of $8.70, Ridgepost Capital has seen a 2.35% 1 day share price return. Its 30 day share price return of 18.77% and 1 year total...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

NeoGenomics PanTracer Pro Launch Sets New Test Against Weak Share Performance

NeoGenomics, NasdaqCM:NEO, has launched PanTracer Pro, a new diagnostic solution for clinicians treating advanced stage solid tumors. The offering combines broad genomic profiling and customized diagnostic testing into a single order with a focus on faster turnaround times. PanTracer Pro is designed to address fragmented testing workflows, treatment delays, and incomplete biomarker assessment in cancer care. NeoGenomics, trading at $11.38, has seen mixed share price performance, with a 30...
NYSE:MH
NYSE:MHConsumer Services

Is McGraw Hill (MH) Pricing Reflect Its Recent Share Price Weakness And Cash Flow Outlook

If you are asking yourself whether McGraw Hill is priced attractively right now, this article will walk through what the current share price might be implying about the business. The stock last closed at US$13.67, with a recent 7 day return of 8.3%, a 30 day return of 5.7% decline, and a year to date return of 16.4% decline, which may have caught your eye if you are watching for changing risk and reward. Recent evergreen coverage interest around McGraw Hill has focused on how the market is...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences (EXAS) Loss Rebound In Q4 Challenges Profitability Progress Narrative

Exact Sciences (EXAS) just reported its FY 2025 numbers with fourth quarter revenue of US$878.4 million, a basic EPS loss of US$0.45 and net income loss of US$86.0 million, while on a trailing twelve month basis revenue came in at about US$3.2 billion with a basic EPS loss of US$1.10 and a net income loss of US$207.9 million. The company has seen quarterly revenue move from US$713.4 million in Q4 2024 to US$878.4 million in Q4 2025, with basic EPS losses over that span ranging from US$4.67 to...